Join us in transforming cell therapy and unlocking a $50B+ market opportunity.Position yourself at the forefront of the cell therapy revolution.
Market Opportunity
- Cell therapy market projected to reach $50B+ by 2030
- Allogeneic therapies represent fastest-growing segment
- 80% of patients currently excluded due to immunosuppression risks
- Platform applicable across oncology, regenerative medicine, and immunology
Competitive Advantages
- Proprietary, patent-protected technology platform
- Validated proof-of-concept in preclinical models
- Experienced leadership team with track record in cell therapy
- Multiple partnership opportunities with leading biotech companies
Development Milestones
-
Preclinical validation complete
Demonstrated efficacy and safety in animal models
-
IND-enabling studies
12-18 months to regulatory submission
-
Phase I clinical trial
First-in-human safety and tolerability
Use of Funds
-
R&D and IND-enabling studies45%
-
Manufacturing and scale-up25%
-
Team expansion20%
-
IP and regulatory10%
What We're Seeking
- Pre-seed Investment
-
Purchase materials and supplies for testing safety and efficacy of complete immune tolerance approach in a large animal model
-
Complete IND-enabling studies for FDA submission
-
Data generated from the studies would position ImmunoShield strongly for a strategic partnership with large pharma
Ready to Transform Cell Therapy?
Join us in making cell therapies accessible to millions of patients worldwide